Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs

被引：0
|
作者：
Emery, P.
Furst, D. E.
Ferraccioli, G.
Udell, J.
Van Vollenhoven, R. F.
Rowe, K.
Agarwa, S.
Shaw, T.
机构：
[1] Leeds Gen Infirm, Dept Rheumatol, Leeds, W Yorkshire, England
[2] Univ Calif Los Angeles, Rheumatol Clin Res Ctr, Los Angeles, CA USA
[3] Catholic Univ, Div Rheumatol, Rome, Italy
[4] Arthritis Grp, Div Rheumatol, Philadelphia, PA USA
[5] Karolinska Univ Hosp, Dept Rheumatol, Stockholm, Sweden
[6] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[7] Genentech Inc, San Francisco, CA 94080 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [21] A call for guidance on the treatment of patients taking disease-modifying anti-rheumatic drugs (DMARDs)
    Dickson, Kirsty Skye
    Regan, Alasdair
    Wemyss, Callum
    Paley, Martin
    Siddiqui, Arshad
    [J]. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2024, 62 (04): : 389 - 390
  • [22] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Roy Fleischmann
    [J]. Clinical Rheumatology, 2021, 40 : 4369 - 4372
  • [23] Safety and Efficacy of Disease-Modifying Anti-Rheumatic AgentsFocus on the Benefits and Risks of Etanercept
    Roy Fleischmann
    Imran Iqbal
    Pallavi Nandeshwar
    Andres Quiceno
    [J]. Drug Safety, 2002, 25 : 173 - 197
  • [24] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Fleischmann, Roy
    [J]. CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
  • [25] Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs
    Akhil Sood
    Mukaila A. Raji
    [J]. Clinical Rheumatology, 2021, 40 : 1221 - 1231
  • [26] Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs
    Sood, Akhil
    Raji, Mukaila A.
    [J]. CLINICAL RHEUMATOLOGY, 2021, 40 (04) : 1221 - 1231
  • [27] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: SAFETY COMPARISON IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO NONBIOLOGIC OR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Burmester, G.
    Charles-Schoemann, C.
    Isaacs, J.
    Hendrikx, T.
    Kwok, K.
    Zwillich, S. H.
    Riese, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 245 - 245
  • [28] Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease-Modifying Anti-Rheumatic Drugs
    Burmester, G. R.
    Charles-Schoeman, C.
    Isaacs, J. D.
    Hendrikx, T.
    Kwok, K.
    Zwillich, S. H.
    Riese, R.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S192 - S192
  • [29] The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs
    Radner, Helga
    Yoshida, Kazuki
    Frits, Michelle
    Iannaccone, Christine
    Shadick, Nancy A.
    Weinblatt, Michael
    Smolen, Josef S.
    Solomon, Daniel H.
    [J]. RHEUMATOLOGY, 2015, 54 (11) : 2076 - 2084
  • [30] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors.
    Keystone, E.
    Fleischmann, R. M.
    Emery, P.
    Chubick, A.
    Dougados, M.
    Baldassare, A. R.
    Bathon, J. M.
    Hessey, E.
    Totoritis, M.
    Cooper, S.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S328 - S328
12345